As a follow up to our November 14, 2006 article, Pharmos Corporation recently announced the completion of another first round of testing of a topical cream used as a drug delivery device for an anti-inflammatory drug. Again, the tests were successful. See "Pharmos completes Phase 1 study of topical Diclofenac NanoEmulsion cream," Law & Health Week via, December 16, 2006.

JCM: It is interesting to compare what Pharmos is doing with its Diclofenac NanoEmulsion to the Cosmetic, Toiletry and Fragrance Association’s October 10, 2006 "Nanotechnology White Paper: The Use of Nanotechnology in Personal Care Products," (maintaining scientific evidence confirms a lack of dermal absorption of nanoparticles).